ArticleActa pharmaceutica Sinica. B2023
Converting bacteria into autologous tumor vaccine
Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Chiral FeBioactive materials · 2026Article
- Review
- Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Optimization Strategies and Synergistic Applications of EngineeredInternational journal of nanomedicine · 2026Review
- Engineered bacteria and bacteria-derived nanomaterials for cancer therapy: Mechanisms, designs and advances.Bioactive materials · 2026Review
- Metal homeostasis as a therapeutic lever: advancing metalloimmunology to remodel the tumor microenvironment and enhance cancer immunotherapy.Theranostics · 2026Review
- Phosphate in Physiological and Pathological Mineralization: Important yet Often Unheeded.MedComm · 2025Review
- Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions.Oncology research · 2025Review
- Nanotechnology-Driven Strategies in Osteosarcoma Advances in Treatment: Immunotherapy and Drug Delivery.International journal of nanomedicine · 2025Review
- Microneedles as transdermal drug delivery system for enhancing skin disease treatment.Acta pharmaceutica Sinica. B · 2024Review
- Personalized nanovaccines for treating solid cancer metastases.Journal of hematology & oncology · 2024Review
- Emerging roles of intratumor microbiota in cancer: tumorigenesis and management strategies.Journal of translational medicine · 2024Review
- The application of bacteria-nanomaterial hybrids in antitumor therapy.Journal of nanobiotechnology · 2024Review
- Repolarizing neutrophils via MnOJournal of nanobiotechnology · 2024Article
- Overcoming the Low-Stability Bottleneck in the Clinical Translation of Liposomal Pressurized Metered-Dose Inhalers: A Shell Stabilization Strategy Inspired by Biomineralization.International journal of molecular sciences · 2024Review
- Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous cancer vaccine that stimulates tumor-specific immune responses for personalized immunotherapy holds great potential for tumor therapy. However, its efficacy is still suboptimal due to the immunosuppressive tumor microenvironment (ITM). Here, we report a new type of bacteria-based autologous cancer vaccine by employing calcium carbonate (CaCO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.